Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
(0:00) Introducing Eli Lilly CEO Dave Ricks (1:43) How Eli Lilly discovered the GLP-1 impact on weight loss, counterfeit products from China (7:08) GLP-1 pricing and capital allocation after a breakout pharma product (12:56) Why Biotech VC has plummeted, "patent hacking" in China (15:32) Dave's health regimen: good…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from All-In with Chamath, Jason, Sacks & Friedberg
See all episodes →
74%The Fight Over Open Source AI, Anthropic's $1.5B Payout, NYC Socialists: Evictions = Violence?
71%Eric Weinstein: The State of American Science, Breakthrough Coverups, and the Danger of Physics
71%Can the AI Industry Regulate Itself? Stripe Wants PayPal, China Catches Up, NY Bans Datacenters
Similar episodes from other shows
More like All-In with Chamath, Jason, Sacks & Friedberg →
Guide to the AI Barnyard, Eli Lilly Hits $1T Valuation, Has AI Ruined the Em Dash? | Julia Steinberg, Bobby Ghoshal
Here's How the New Weight Loss Drugs Could Change Everything
Corner Office Conversation with Eli Lilly's Global CEO David Ricks
Healthcare is Broken—This Company Wants to Fix It
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.